Fennec Pharmaceuticals Inc

FENC remains in a high-confidence Stage 2 advancing uptrend with an active momentum breakout confirming medium-term bullish structure, but price is currently extended above rising EMAs with overbought RSI and options score, making short-term execution unfavorable; deferred entries on a healthy pullback into support are advised.

• ↑Q1 2026 net product sales rose 73% YoY to $15.1M
• ↑Generated positive cash flow in Q1; holds $40.1M in cash
• ↓Profitability remains weak; Q1 operating expenses hit ~$14M